Breaking News

Ambrx Appoints CEO

January 7, 2013

Macartney brings 20 years of pharma experience

Lawson Macartney, Ph.D., DVM, has been appointed president and chief executive officer of Ambrx, and a member of the board of directors. Dr. Macartney has more than 20 years of experience in the pharma industry. Most recently, he served as senior vice president and head of the emerging business unit at Shire Pharmaceuticals, where he contributed to growing and diversifying the clinical pipeline.
Prior to joining Shire in 2011, Mr. Macartney was senior vice president of global product strategy and project/portfolio management for GlaxoSmithKline, where he spent four years overseeing the commercial evaluation and commercial strategy for assets at all stages of development and identifying in-licensing opportunities. He held additional positions at GlaxoSmithKline, Astra Pharmaceuticals and Ribozyme Pharmaceuticals.
"We are excited to have Lawson lead Ambrx as our pipeline of therapeutics, including our drug conjugates, continues to grow and mature," said John Diekman, Ph.D., chairman of Ambrx's board of directors. "Ambrx has demonstrated the strength of its technology base and pipeline through data and collaborations, and now we believe Lawson's expertise positions him to lead the company in the next stage of its growth."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks